Skip to main navigation menu Skip to main content Skip to site footer

Focus Topic

No 2 (2016): Life Sciences

Die heilmittelrechtliche Qualifikation von nanotechnologischen drug-delivery-Produkten

  • Marcel Lanz
Submitted
March 14, 2018
Published
March 14, 2018

Abstract

New challenges may arise for regulators to authorize nanomedicines being put on the market. Uncertainty about possible risks concerning nanomedicines requires these products to be considered as medicines, and not as medicinal products. Established toxicity tests need to be specifically adapted to nanomedicines.